Merck (MRK) Tops Q3 EPS by 10c

Merck (NYSE: MRK) reported Q3 EPS of $1.85, $0.10 better than the analyst estimate of $1.75. Revenue for the quarter came in at $15 billion versus the consensus estimate of $14.07 billion.

GUIDANCE:

Merck sees FY2022 EPS of $7.32-$7.35, versus the consensus of $7.34. Merck sees FY2022 revenue of $58.5-59 billion, versus the consensus of $58.51 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
• Bernstein sees downside risk to Apple's December quarter results